AI Article Synopsis
- Monitoring liver fibrosis (LF) is crucial for managing liver complications in patients co-infected with HIV and HCV.
- A study compared LF progression in 50 HIV/HCV co-infected patients with 115 HCV mono-infected patients over several years, finding that around 76% of co-infected and 75% of mono-infected patients remained stable in their LF stage.
- While 19% of co-infected and 15% of mono-infected patients progressed to advanced LF, the rates were similar, with alcohol abuse being the only significant risk factor for progression.
Article Abstract
Monitoring of liver fibrosis (LF) is an essential tool for preventing liver-related complications in HIV/HCV co-infected patients. In this study, we compared LF progression by transient elastometry (TE) in 50 HIV/HCV co-infected and 115 HCV mono-infected patients followed in our institution between June 2006 and December 2011. Patients naive to interferon therapy and with at least two measurements of liver stiffness by TE were included. In all, 76% of HIV/HCV co-infected and 75% of HCV mono-infected patients remained in the same stage of LF over time. Conversely, 19% and 15% of HIV/HCV co-infected and HCV mono-infected subjects, respectively, had progression to advanced LF (≥ F3). Our study found a similar proportion of HIV/HCV co-infected and HCV mono-infected patients that developed an advanced LF during the follow-up time considered. Alcohol abuse was the only factor significantly associated with the progression as evidenced by multiple quantile regression analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365548.2014.952245 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!